Trasylol lawsuits continue to be filed around the United States on behalf of patients suffering from kidney failure and stroke problems and families who are pursuing wrongful death claims on behalf of loved ones who died following heart surgery. The Supreme Court is set to hear the case of Wyeth v. Levine later this year. This case centers on the question of whether a patient who has been harmed by a drug can sue under state law if the drug was approved by the FDA.The potential effect of this decision cannot be underestimated. People injured by defective drugs, including people who have filed a Trasylol lawsuit, will be affected by the Supreme Court’s decision in this case.
The top doctors at the New England Journal of Medicine (NEJM) have come out and strongly stated their opinion along with 47 state attorneys general and two former FDA commissioners, David Kestrel and Donald Kennedy. The journal editors asked the justices to carefully consider how overwhelmed the FDA is and to weigh that against patient safety stating:
“The FDA alone simply lacks the ability to serve as the sole guarantor of drug safety,” the doctors said in a brief filed Thursday. Without the discoveries dredged up by plaintiffs’ lawyers through liability litigation, “the FDA would be stripped of an essential source of information that the agency has consistently relied on when making its regulatory decisions and the American public would be deprived of a vital deterrent against pharmaceutical company misconduct.”
The Wyeth case involves Diana Levine, a Vermont guitarist, who was injected with Phenergan, a medication for nausea, and subsequently developed gangrene which led to the amputation of her arm. She sued the drug’s manufacturer Wyeth, arguing that the manufacturer failed to adequately warn consumers about the risks of the injections. The NEJM editors and scores of others concerned with patient safety are worried that the rights of patients are eroded in the face of preemption arguments aimed to protect drug companies. Proponents of preemption stand by their position that the FDA weighs the risks and benefits of a drug’s safety and after approval the drug manufacturer should be protected from lawsuits by consumers who were injured by the approved drug.
We are a Law Firm that is dedicated to helping people who have been affected by Trasylol side effects.
Personal Injury Law Firm
Patients and families nationwide have looked at filing a Trasylol lawsuit based on the often fatal side effects of the drug Trasylol. Currently no Trasylol class action suits have been filed by Fields Law Firm and claims are being made individually.
The lawsuits claim that Bayer, the drug’s manufacturer, was negligent in several ways including:
• marketing [...]
The Trasylol heart surgery drug has increasingly been linked to serious side effects including kidney failure and stroke following bypass surgery. Many patients and families have questioned whether Bayer’s heart medication, also referred to as “Aprotinin“, was used during their procedure. The problem is that without looking at the medical records from the day of [...]
Bayer’s widely used Trasylol heart surgery drug was subject to a recall in 2007 following a study that raised safety concerns. Prior to the recall, Trasylol (also referred to as Aprotinin) was used to help prevent excessive bleeding during open heart surgery. The study reported that Bayer’s heart surgery medication increased the risk of dying [...]
Following a Trasylol recall in 2007, Bayer’s heart surgery drug continued to be used during heart surgery even though cheaper and safer alternative drugs were available. Unfortunately, Trasylol was used until as recently as May 2008.In 1993, Trasylol (also referred to as “aprotinin”) received FDA approval for use in certain types of heart surgeries. Until [...]
Bayer’s problems are growing as they face thousands of potential Trasylol lawsuits following increasing reports of their heart surgery drug’s side effects. Trasylol has recently been linked to a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved [...]